Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

Roche announced positive interim phase III data from the IMAgINATION study showing that investigational sefaxersen achieved a statistically significant 43.1% reduction in proteinuria relative to placebo at 37 weeks in adults with primary IgA nephropathy. The antisense oligonucleotide inhibitor of complement factor B was well tolerated with no new safety signals and is designed as a once-monthly subcutaneous injection for self-administration.